Cipla is currently trading at Rs. 590.40, up by 1.50 points or 0.25% from its previous closing of Rs. 588.90 on the BSE.
The scrip opened at Rs. 590.00 and has touched a high and low of Rs. 591.90 and Rs. 585.10 respectively. So far 58,000 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 621.90 on 06-Feb-2017 and a 52 week low of Rs. 458.25 on 25-May-2016.
Last one week high and low of the scrip stood at Rs. 600.55 and Rs. 585.10 respectively. The current market cap of the company is Rs. 47,498.00 crore.
The promoters holding in the company stood at 37.49%, while Institutions and Non-Institutions held 35.64% and 26.87% respectively.
Cipla’s wholly owned subsidiary in USA - Cipla USA Inc., has signed a worldwide licensing agreement (except for East Asia) with MEDRx Company (MEDRx) to further develop and commercialize MRX-4TZT, a Tizanidine patch for the management of Spasticity.
Under the terms of the agreement, MEDRx is eligible to receive up to $30 million cumulatively through upfront and developmental, regulatory, and commercial milestones payments. MEDRx will also receive tiered royalties on the net sales of commercialized licensed products.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For 80 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 100 countries.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1850.40 |
| Dr. Reddys Lab | 1310.50 |
| Cipla | 1365.25 |
| Zydus Lifesciences | 939.10 |
| Lupin | 2442.35 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: